Twist Bioscience (TWST) revenue

Revenue · fiscal 2026
$459.43M

Twist Bioscience (TWST) reported revenue of $459.43M in fiscal 2026 (the year ended September 30, 2026). That is 22.0% higher than the $376.57M of fiscal 2025. Figures as of 18 Nov 2026, 10:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2026
$459.43M
Change on fiscal 2025
+22.0%
Growth, 5 years
+28.3% a year
Highest on record
$459.43Mfiscal 2026
Lowest on record
$10.77Mfiscal 2017
Fiscal years on record
102017–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Twist Bioscience revenue, in more detail

Over the five fiscal years to 2026 revenue grew at a compound 28.3% a year. Across the 10 fiscal years on record (2017–2026), the highest was $459.43M in fiscal 2026 and the lowest $10.77M in fiscal 2017.

History · 10 fiscal years

Revenue by fiscal year

Twist Bioscience revenue, year by year

Twist Bioscience (TWST) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2026$459.43M 22.0% up
2025$376.57M 20.3% up
2024$312.97M 27.7% up
2023$245.11M 20.4% up
2022$203.57M 53.8% up
2021$132.33M 46.9% up
2020$90.10M 65.7% up
2019$54.39M 113.9% up
2018$25.43M 136.2% up
2017$10.77M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Twist Bioscience and comparable companies
CompanyRevenueFiscal year
TG Therapeutics TGTX$616.29M2025
Praxis Precision Medicines PRAX$8.55M2024
Twist Bioscience TWST$459.43M2026
Protagonist Therapeutics PTGX$46.02M2025
Krystal Biotech KRYS$389.13M2025
10x Genomics TXG$642.82M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TWST

Twist Bioscience, figure by figure

Twist Bioscience (TWST) overview: price, valuation and scorecardAll health care companies by market value

Twist Bioscience revenue: questions and answers

What is Twist Bioscience's revenue?

Twist Bioscience (TWST) reported revenue of $459.43M in fiscal 2026 (the year ended September 30, 2026). That is 22.0% higher than the $376.57M of fiscal 2025.

What is the growth rate of Twist Bioscience's revenue?

Over the five fiscal years to 2026 revenue grew at a compound 28.3% a year.

What are the highest and lowest revenue figures on record for Twist Bioscience?

Across the 10 fiscal years on record (2017–2026), the highest was $459.43M in fiscal 2026 and the lowest $10.77M in fiscal 2017.

How is Twist Bioscience's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Twist Bioscience it is on record here for 10 fiscal years, 2017 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Twist Bioscience (TWST) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/TWST/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.